Search
 
NEWS
 

In R/R CLL, Zanubrutinib Offers 35% Improved PFS Over Ibrutinib; Edge Greater for Higher-Risk Patients - AJMC.com Managed Markets Network

 
 
Results from the ALPINE trial were presented Tuesday at a late-breaking session of the 64th American Society of Hematology Annual Meeting and Exposition, held in New Orleans, Louisiana. - READ MORE
By AJMC.com Managed Markets Network
Tue, 13 Dec 2022 15:04:36 GMT
 
PREVIOUS NEXT
Perspective | Toys R Us may have grown up, but the pandemic is fueling its rebirth - The Washington Post
Alexander R. Caron | News, Sports, Jobs - Nashua Telegraph
Trinity Life Sciences Announces the Appointment of Paul R. Lucchese as General Counsel - Business Wire
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL - Targeted Oncology
Trenton R-9 Board of Education announces meeting results from Tuesday, December 13, 2022 - kttn
The New Honda Civic Type R Is Going Racing in 2023 - Car and Driver
An Introduction To Using R For SEO - Search Engine Journal
Community R-6 teams split home twinbill with Slater - Mexico Ledger
Tagged: #In #Zanubrutinib #Offers #Improved #PFS #Over #Edge #Greater #Patients #Managed #Markets #Network
ADD COMMENT
Topic
Name
9+1 =